JP2010509234A - 新生物疾患、自己免疫疾患および炎症性疾患を処置する方法 - Google Patents

新生物疾患、自己免疫疾患および炎症性疾患を処置する方法 Download PDF

Info

Publication number
JP2010509234A
JP2010509234A JP2009535486A JP2009535486A JP2010509234A JP 2010509234 A JP2010509234 A JP 2010509234A JP 2009535486 A JP2009535486 A JP 2009535486A JP 2009535486 A JP2009535486 A JP 2009535486A JP 2010509234 A JP2010509234 A JP 2010509234A
Authority
JP
Japan
Prior art keywords
antibody
patient
cells
leukemia
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009535486A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010509234A5 (enExample
Inventor
ジョナサン ジー． ドラックマン，
メイ キュング サザーランド，
エリック ジーバース，
グラント リスドン，
エゾゲリン オフラゾグリュ，
アラン ワール，
ティム ルイス，
Original Assignee
シアトル ジェネティックス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シアトル ジェネティックス， インコーポレイテッド filed Critical シアトル ジェネティックス， インコーポレイテッド
Publication of JP2010509234A publication Critical patent/JP2010509234A/ja
Publication of JP2010509234A5 publication Critical patent/JP2010509234A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2009535486A 2006-11-02 2007-11-02 新生物疾患、自己免疫疾患および炎症性疾患を処置する方法 Pending JP2010509234A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US85653006P 2006-11-02 2006-11-02
US87443906P 2006-12-11 2006-12-11
US94302107P 2007-06-08 2007-06-08
PCT/US2007/083508 WO2008058021A2 (en) 2006-11-02 2007-11-02 Methods of treating neoplastic, autoimmune and inflammatory diseases

Publications (2)

Publication Number Publication Date
JP2010509234A true JP2010509234A (ja) 2010-03-25
JP2010509234A5 JP2010509234A5 (enExample) 2010-12-16

Family

ID=39365271

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009535486A Pending JP2010509234A (ja) 2006-11-02 2007-11-02 新生物疾患、自己免疫疾患および炎症性疾患を処置する方法

Country Status (6)

Country Link
US (3) US20110038856A1 (enExample)
EP (1) EP2084527A4 (enExample)
JP (1) JP2010509234A (enExample)
AU (1) AU2007317333A1 (enExample)
CA (1) CA2667808A1 (enExample)
WO (1) WO2008058021A2 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106794266A (zh) * 2014-07-01 2017-05-31 安普希韦纳治疗公司 双特异性cd33和cd3结合蛋白
JP2018533909A (ja) * 2015-08-28 2018-11-22 アムニクス オペレーティング インコーポレイテッド キメラポリペプチドアセンブリーならびにそれを作製および使用する方法
US10738118B2 (en) 2015-05-29 2020-08-11 Amphivena Therapeutics, Inc. Methods of using bispecific CD33 and CD3 binding proteins

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1392359T4 (da) 2001-05-11 2013-06-10 Ludwig Inst For Cancer Res Ltd Specifikke bindingsproteiner og deres anvendelser.
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
US20110038856A1 (en) * 2006-11-02 2011-02-17 Seattle Genetics, Inc. Methods of treating neoplastic, autoimmune and inflammatory diseases
US9090693B2 (en) 2007-01-25 2015-07-28 Dana-Farber Cancer Institute Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease
JP5618549B2 (ja) 2007-03-15 2014-11-05 ルードヴィッヒ インスティテュート フォー キャンサーリサーチ リミテッド Ｅｇｆｒ抗体及びｓｒｃ阻害剤を用いる治療方法及び関連製剤
US7906117B2 (en) 2007-05-21 2011-03-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
US8404235B2 (en) 2007-05-21 2013-03-26 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US9701747B2 (en) 2007-05-21 2017-07-11 Alderbio Holdings Llc Method of improving patient survivability and quality of life by anti-IL-6 antibody administration
DK2164514T3 (en) 2007-05-21 2017-02-27 Alderbio Holdings Llc Antibodies to IL-6 and its use
US8062864B2 (en) 2007-05-21 2011-11-22 Alderbio Holdings Llc Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
US8178101B2 (en) 2007-05-21 2012-05-15 Alderbio Holdings Inc. Use of anti-IL-6 antibodies having specific binding properties to treat cachexia
US8252286B2 (en) 2007-05-21 2012-08-28 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
JP5532486B2 (ja) 2007-08-14 2014-06-25 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ Ｅｇｆ受容体を標的とするモノクローナル抗体１７５ならびにその誘導体および用途
CA2722184A1 (en) 2008-04-25 2009-10-29 Duke University Regulatory b cells and their uses
US8420089B2 (en) 2008-11-25 2013-04-16 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US8337847B2 (en) 2008-11-25 2012-12-25 Alderbio Holdings Llc Methods of treating anemia using anti-IL-6 antibodies
US9212223B2 (en) 2008-11-25 2015-12-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US9452227B2 (en) 2008-11-25 2016-09-27 Alderbio Holdings Llc Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
US8992920B2 (en) 2008-11-25 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of arthritis
US8323649B2 (en) 2008-11-25 2012-12-04 Alderbio Holdings Llc Antibodies to IL-6 and use thereof
CN102264372B (zh) * 2009-08-31 2012-07-11 西安力邦医药科技有限责任公司 氟维司群纳米球/微球及其制备方法和用途
EP2476438B1 (en) 2009-09-10 2014-07-23 Kyowa Hakko Kirin Co., Ltd. Medicament including antibody composition specifically bound to human cc chemokine receptor 4 (ccr4)
EP2504032A4 (en) 2009-11-24 2013-06-19 Alderbio Holdings Llc IL-6 ANTAGONISTS FOR PREVENTING OR TREATING THROMBOSIS
US9775921B2 (en) 2009-11-24 2017-10-03 Alderbio Holdings Llc Subcutaneously administrable composition containing anti-IL-6 antibody
WO2011075185A1 (en) 2009-12-18 2011-06-23 Oligasis Targeted drug phosphorylcholine polymer conjugates
EP2600878A4 (en) 2010-08-04 2014-06-11 Univ Duke REGULATORY B-CELLS AND ITS USES
UA112062C2 (uk) * 2010-10-04 2016-07-25 Бьорінгер Інгельхайм Інтернаціональ Гмбх Cd33-зв'язувальний агент
GB201016864D0 (en) 2010-10-06 2010-11-17 Univ Aston Therapeutic methods
US8992908B2 (en) 2010-11-23 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of oral mucositis
WO2012088272A1 (en) * 2010-12-21 2012-06-28 Duke University Methods and compositions combining immunotherapy with monocyte activation
US10017739B2 (en) 2012-09-06 2018-07-10 Duke University Methods of expanding and assessing B cells and using expanded B cells to treat disease
HK1212448A1 (en) 2012-09-07 2016-06-10 The Governors Of The University Of Alberta Methods and compositions for diagnosis of inflammatory liver disease
JP6673696B2 (ja) 2012-09-28 2020-03-25 クライン，エリス 感染症治療用グリコシダーゼレジメン
US20150352193A1 (en) * 2013-01-18 2015-12-10 Ellis Kline Selective glycosidase regimen for immune programming and treatment of cancer
US20160030558A1 (en) * 2013-03-13 2016-02-04 Health Research, Inc. Enhancement of vaccines
AR097648A1 (es) * 2013-09-13 2016-04-06 Amgen Inc Combinación de factores epigenéticos y compuestos biespecíficos que tienen como diana cd33 y cd3 en el tratamiento de leucemia mieloide
GB201319620D0 (en) * 2013-11-06 2013-12-18 Norwegian University Of Science And Technology Immunosuppressive agents and their use in therapy
WO2015085171A1 (en) * 2013-12-06 2015-06-11 Adventist Health Systems/Sunbelt, Inc. Role of mcp-1 in relapse of acute myeloid leukemia after hematopoietic stem cell transplantation
AU2016276981B2 (en) 2015-06-12 2022-10-06 Alector Llc Anti-CD33 antibodies and methods of use thereof
EP3307779A2 (en) 2015-06-12 2018-04-18 Alector LLC Anti-cd33 antibodies and methods of use thereof
WO2017160954A1 (en) 2016-03-15 2017-09-21 Seattle Genetics, Inc. Combinations of pbd-based antibody drug conjugates with bcl-2 inhibitors
JOP20170091B1 (ar) * 2016-04-19 2021-08-17 Amgen Res Munich Gmbh إعطاء تركيبة ثنائية النوعية ترتبط بـ cd33 وcd3 للاستخدام في طريقة لعلاج اللوكيميا النخاعية
WO2017210621A1 (en) 2016-06-03 2017-12-07 Seattle Genetics, Inc. Combination of cd33 antibody drug conjugates with chemotherapeutic agents
WO2017214433A1 (en) 2016-06-09 2017-12-14 Seattle Genetics, Inc. Combinations of pbd-based antibody drug conjugates with flt3 inhibitors
JP7252627B2 (ja) 2016-12-15 2023-04-05 デューク ユニバーシティ 制御性ｂ１０細胞を枯渇させる抗体および方法並びに免疫チェックポイント阻害剤との併用における使用
MY205541A (en) 2017-08-03 2024-10-25 Alector Llc Anti-cd33 antibodies and methods of use thereof
WO2019094931A1 (en) * 2017-11-10 2019-05-16 Actinium Pharmaceuticals, Inc. Combination therapy for treatment of a hematological disease
AR119259A1 (es) 2018-08-31 2021-12-09 Alector Llc Anticuerpos anti-cd33 y métodos de uso de los mismos
EP3863644A4 (en) * 2018-10-12 2022-10-05 Jeanmarie Guenot CD33×CD3-BINDING PROTEINS FOR THE TREATMENT OF INFLAMMATORY CONDITIONS AND DISEASES
JP7711945B2 (ja) 2019-04-30 2025-07-23 センティ バイオサイエンシズ インコーポレイテッド キメラ受容体及びその使用方法
US20220331247A1 (en) * 2019-09-23 2022-10-20 Association For The Advancement Of Tissue Engineering And Cell Based Technologies & Therapies A4Tec Polymeric micelle, methods of production and uses thereof
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
KR102393676B1 (ko) * 2020-10-08 2022-05-04 주식회사 큐롬바이오사이언스 베타-라파촌을 유효성분으로 포함하는 담즙 정체성 간질환 예방 또는 치료용 약학 조성물
WO2023081898A1 (en) 2021-11-08 2023-05-11 Alector Llc Soluble cd33 as a biomarker for anti-cd33 efficacy

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001502888A (ja) * 1996-08-09 2001-03-06 ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド Ｃｄ３３様タンパク質をコードするヌクレオチド配列
JP2004505994A (ja) * 2000-08-08 2004-02-26 イムノメディクス，　インコーポレイテッド 慢性骨髄性白血病の免疫療法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US20040049014A1 (en) * 1988-12-28 2004-03-11 Protein Design Labs, Inc. Humanized immunoglobulins
EP0504327B1 (en) * 1989-12-14 2000-09-20 Sloan-Kettering Institute For Cancer Research Therapeutic uses of the hypervariable region of monoclonal antibody m195 and constructs thereof
US6599505B1 (en) * 1992-04-10 2003-07-29 Research Development Foundation Immunotoxins directed against CD33 related surface antigens
US6007814A (en) * 1992-06-15 1999-12-28 Sloan-Kettering Institute For Cancer Research Therapeutic uses of the hypervariable region of monoclonal antibody M195 and constructs thereof
US6653104B2 (en) * 1996-10-17 2003-11-25 Immunomedics, Inc. Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells
US7194554B1 (en) * 1998-12-08 2007-03-20 Nomadix, Inc. Systems and methods for providing dynamic network authorization authentication and accounting
US20040152632A1 (en) * 2002-11-06 2004-08-05 Wyeth Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome
WO2004043461A1 (en) * 2002-11-06 2004-05-27 Wyeth Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome
DK1578446T3 (en) * 2002-11-07 2015-06-29 Immunogen Inc ANTI-CD33 ANTIBODIES AND PROCEDURES FOR TREATING ACUTE MYELOID LEUKEMIA BY USING IT
CN101083998A (zh) * 2004-11-22 2007-12-05 王者制药研究发展有限公司 用腺苷a3受体激动剂强化治疗hif－1介导的病症
US8420783B2 (en) * 2004-12-08 2013-04-16 Immunomedics, Inc. Method and compositions for immunotherapy of inflammatory and immune-dysregulatory diseases
US20110038856A1 (en) 2006-11-02 2011-02-17 Seattle Genetics, Inc. Methods of treating neoplastic, autoimmune and inflammatory diseases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001502888A (ja) * 1996-08-09 2001-03-06 ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド Ｃｄ３３様タンパク質をコードするヌクレオチド配列
JP2004505994A (ja) * 2000-08-08 2004-02-26 イムノメディクス，　インコーポレイテッド 慢性骨髄性白血病の免疫療法

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106794266A (zh) * 2014-07-01 2017-05-31 安普希韦纳治疗公司 双特异性cd33和cd3结合蛋白
JP2017521415A (ja) * 2014-07-01 2017-08-03 アンフィヴェナ セラピューティクス，インク． 二重特異性ｃｄ３３およびｃｄ３結合タンパク質
US10626190B2 (en) 2014-07-01 2020-04-21 Amphivena Therapeutics, Inc. Bispecific CD33 and CD3 binding proteins
CN106794266B (zh) * 2014-07-01 2021-02-23 安普希韦纳治疗公司 双特异性cd33和cd3结合蛋白
CN112851820A (zh) * 2014-07-01 2021-05-28 安普希韦纳治疗公司 双特异性cd33和cd3结合蛋白
JP2022068346A (ja) * 2014-07-01 2022-05-09 アンフィヴェナ セラピューティクス，インク． 二重特異性ｃｄ３３およびｃｄ３結合タンパク質
CN112851820B (zh) * 2014-07-01 2023-11-28 安普希韦纳治疗公司 双特异性cd33和cd3结合蛋白
US10738118B2 (en) 2015-05-29 2020-08-11 Amphivena Therapeutics, Inc. Methods of using bispecific CD33 and CD3 binding proteins
US11753469B2 (en) 2015-05-29 2023-09-12 Anji Bruno, Llc Methods of using bispecific CD33 and CD3 binding proteins
JP2018533909A (ja) * 2015-08-28 2018-11-22 アムニクス オペレーティング インコーポレイテッド キメラポリペプチドアセンブリーならびにそれを作製および使用する方法
JP2021178831A (ja) * 2015-08-28 2021-11-18 アムニクス ファーマシューティカルズ， インコーポレイテッド キメラポリペプチドアセンブリーならびにそれを作製および使用する方法
JP2024105275A (ja) * 2015-08-28 2024-08-06 アムニクス ファーマシューティカルズ， インコーポレイテッド キメラポリペプチドアセンブリーならびにそれを作製および使用する方法

Also Published As

Publication number Publication date
US7695716B2 (en) 2010-04-13
WO2008058021A3 (en) 2008-07-03
US20110038856A1 (en) 2011-02-17
US20080267960A1 (en) 2008-10-30
US20100215653A1 (en) 2010-08-26
EP2084527A2 (en) 2009-08-05
EP2084527A4 (en) 2011-07-27
WO2008058021A2 (en) 2008-05-15
AU2007317333A1 (en) 2008-05-15
CA2667808A1 (en) 2008-05-15

Similar Documents

Publication Publication Date Title
US7695716B2 (en) Methods of treating neoplastic, autoimmune and inflammatory diseases
JP4303964B2 (ja) 組換え抗ｃｄ３０抗体およびその使用
JP2022137076A (ja) 抗ｃｄ３３抗体及びその使用方法
KR101197542B1 (ko) 항-ｃｄ20 항체 및 이용 방법
KR102663440B1 (ko) 인간화된 항-ccr7 리셉터 항체
KR102110557B1 (ko) 치료 항체 및 그의 용도
JP2020517302A (ja) Ｃｄ１９に対するヒト化抗原結合ドメイン及び使用方法
KR20100094527A (ko) 백혈병 줄기세포의 억제 방법
JP2022538733A (ja) 新規抗ｃｄ２５抗体
IL188594A (en) Anti-ccr7 receptor antibodies for the treatment of cancer
KR20230093010A (ko) 신규 항-lilrb2 항체 및 유도체 생성물
TW202116807A (zh) 用於治療特定患者之癌症的抗體組合
JP2023533793A (ja) 治療用抗体およびそれらの使用
TWI857982B (zh) 特異性結合至ｃｄ２０的單株抗體
JP2023523890A (ja) Ｈｓｐ７０を標的とするモノクローナル抗体およびその治療的使用
US20210032360A1 (en) Antibodies against bst1 for preventing or treating myelodysplastic syndrome
WO2023010483A1 (en) Anti-human cxcr5 antibody and uses thereof
WO2022192423A1 (en) Anti-human cxcr5 antibody and uses thereof
WO2025026333A1 (en) Antibody against fgfr2b, method for preparing the same, and use thereof
BR112020001320A2 (pt) combinações farmacêuticas que compreendem um anticorpo anti-bst-1 e um análogo de citidina
WO2025179282A1 (en) Antibodies targeting epstein-barr virus proteins and methods of use
HK1124760A (en) Anti-ccr7 receptor antibodies for the treatment of cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101025

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20101025

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111004

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120927

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130313